Characterization of Fibrodysplasia in the Dog Following Inhibition of Metalloproteinases

Toxicologic Pathology

Volumn 37, Issue 7, 2009, Pages 860-872

  Westwood, Russell ^a   Scott, Robert C ^a   Somers, Rebecca L ^a   Coulson, Michelle ^a   Maciewicz, Rose A ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

dermal toxicity; dog pathology; drug development; histopathology; integumentary system; metalloproteinase; musculoskeletal system

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AZM 551248; AZM551248; COLLAGEN TYPE 1; COLLAGEN TYPE 3; FIBRONECTIN; MATRIX METALLOPROTEINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ACHILLES TENDON; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; AUTOPSY; CELL DIFFERENTIATION; CELL PROLIFERATION; CONNECTIVE TISSUE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG INDUCED DISEASE; FEMALE; FIBROUS DYSPLASIA; HISTOPATHOLOGY; KIDNEY DYSPLASIA; MALE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS TISSUE;

ANIMALS; CONNECTIVE TISSUE; DOGS; FIBROSIS; METALLOPROTEASES; PIPERAZINES; PROTEASE INHIBITORS; TENDONS; TOXICITY TESTS;

ANIMALIA; CANIS FAMILIARIS;

EID: 74949111415     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/0192623309347909     Document Type: Article

References (35)

1. Chang C Werb Z The many faces of metalloproteinases: cell growth, invasion, angiogenesis and metastasis Trends Cell Biol 2001 11 S37 S43
2. Clark IM Parker EP Metalloproteinases: Their role in arthritis and potential as therapeutic targets Exp Opin Ther Targets 2003 7 19 34
3. Coussens LM Fingleton B Matrisian LM Matrix metalloproteinase inhibitors and cancer: Trials and tribulations Science 2002 295 2387 92
4. Davidson RK Waters JG Kevorkian L Darrah C Cooper A Donell ST Clark IM Expression profiling of metalloproteinases and their inhibitors in synovium and cartilage Arthritis Res Ther 2006 8 R124
5. Desmouliere A Geinoz A Gabbiani F Gabbiani G Transforming growth factor-β1 induces α-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts J Cell Biol 1993 122 103 11
6. Drummond AH Becket P Brown PD Bone EA Davidson AH Galloway WA Gearing AJ Huxley P Laber D McCourt M Whittaker M Wood LM Wright A Preclinical and clinical studies of MMP inhibitors in cancer Ann N Y Acad Sci 1999 878 228 35
7. Gabbiani G The myofibroblast in wound healing and fibrocontractive diseases J Pathol 2003 200 500 3
8. Gabbiani G Le Lous M Bailey AG Bazin S Delaunay A Collagen and myofibroblasts of granulation tissue: A chemical, ultrastructural and immunologic study Virchows Archiv B Cell Pathol 1976 21 133 45
9. Hinz B Phan SH Thannickal VJ Galli A Bochaton-Piallat M Gabbiani G The myofibroblast: One function, multiple origins Am J Pathol 2007 170 1807 16
10. Hodgson JA Remodeling MMPIs Biotechnology 1995 30 554 57
11. Holmbeck K Bianco P Caterino J Yamada S Kromer M Kuznetsov SA Mankani M Robey PG Poole AR Pidoux I Ward JM Birkedal-Hansen H MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis and connecctive tissue disease due to inadequate collagen turnover Cell 1999 99 81 92
12. Hutchinson JW Tierney GM Parsons SL Davis TR Dupuytren’s disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor Journal of Bone and Joint Surgery–British Volume 1998 80 907 8
13. Johnson AR Pavlovsky AG Ortwine DF Prior F Man C Bornemeier DA Banotai CA Mueller WT McConnell P Yan C Baragi V Lesch C Roark WH Wilson M Datta K Guzman R Han H Dyer RD Discovery and characterization of a novel inhibitor of matrix metalloproteinase-13 (MMP-13) that reduces cartilage damage in vivo without joint fibroplasia side effects J Biol Chem 2007 282 27781 91
14. Knauper V Lopez-Otin C Smith B Knight G Murphy G Biochemical characterization of human collagenase-3 J Biol Chem 1996 271 1544 50
15. Krzeski P Buckland-Wright C Balint G Cline GA Stoner R Lyon R Beary J Aronstein WS Spector TD Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patiants with knee osteoarthritis: A randomized, 12-month, double-blind, placebo-controlled study Arthritis Res Ther 2007 9 R109
16. Levi E Fridman R Miao HQ Ma YS Yayon A Vlodavsky I Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1 Proc Natl Acad Sci U S A 1996 93 7069 74
17. Lohi J Wilson CL Roby JD Parks WC Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury J Biol Chem 2001 276 10134 44
18. Martignetti JA Al Aqueel A Al Sewairi W Boumah CE Kambouris M Al Mayouf S Sheth KV Al Eid W Dowling O Harris J Glucksman MJ Bahabri S Meyer BF Desnick RJ Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome Nat Genet 2001 28 261 65
19. Maxie MG Newman SJ Maxie MG Urinary system Jubb, Kennedy, and Palmer’s pathology of domestic animals 2007 5th ed Edinburg, New York New Elsevier Saunders 439 42
20. McCawley LJ Matrisian LM Matrix metalloproteinases: They’re not just for the matrix anymore Curr Opin Cell Biol 2001 13 534 40
21. Murphy G Knauper V Atkinson S Butler G English W Hutton M Stracke J Clark I Matrix mettalloproteinases in arthritic disease Arthritis Res 2002 4 Suppl 3 S39 49
22. Nemunaitis J Poole C Primrose J Rosemurgy A Malfetano J Brown P Berrington A Cornish A Lynch K Rasmussen H Kerr D Cox D Millar A Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of biologically active and tolerable dose for long-term studies Clin Cancer Res 1998 4 1101 9
23. Peterson JT Matrix metalloproteinase inhibitor development and the remodelling of drug discovery Heart Fail Rev 2004 9 63 79
24. Peterson JT The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors Cardiovasc Res 2006 69 677 87
25. Renkiewicz R Qiu L Lesch C Sun X Devalaraja TC Kaldjian E Welgus H Baragi V Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats Arthritis Rheum 2003 48 1742 49
26. Rosemurgy A Harris J Langleben A Casper E Goode S Rasmussen H Marimastat in patients with advanced pancreatic cancer: A dose finding study Am J Clin Oncol 1999 22 247 52
27. Serini G Bochaton-Piallat ML Ropraz P Geinoz A Borsi L Zardi L Gabbiani G The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-β1 J Cell Biol 1998 142 873 81
28. Shalinsky DR Shetty B Pithavala Y Bender S Neri A Webber S Appelt K Collier M Clendeninn NJ Appelt K Prinomastat. A potent selective matrix metalloproteinase inhibitor–preclinical and clinical development for oncology Cancer drug discovery and development: Matrix metalloproteinase inhibitors in cancer therapy 2000 Totowa, NJ Humana Press Inc 143 73
29. Tierney GM Griffin NR Stuart RC Kasem H Lynch KP Lury JT Brown PD Millar AW Steele RJ Parsons SL A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer Eur J Cancer 1999 35 563 68
30. Tomasek JJ Gabbiani G Hinz B Chaponnier C Brown RA Myofibroblasts and mechano-regulation of connective tissue remodelling Nat Rev Mol Cell Biol 2002 3 349 63
31. Visse R Nagase H Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Structure, function, and biochemistry Circ Res 2003 92 827 39
32. Whittaker M Floyd CD Brown P Gearing AJH Design and therapeutic application of matrix metalloproteinase inhibitors Chem Rev 1999 99 2735 76
33. Wojtowicz-Praga S Torri J Johnson M Steen V Marshall J Ness E Dickson R Sale M Rasmussen HS Ciodod TA Hawkins MJ Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer J Clin Oncol 1998 16 2150 56
34. Yu Q Stamenkovie I Cell surface-localized matrix metalloproteinase 9 proteolytically activates TGF-β and promotes tumour invasion and angiogenesis Genes Dev 2000 14 163 76
35. Zhou Z Apte SS Soininen R Cao R Baaklini GY Rauser RW Wang J Cao Y Tryggvason K Impaired endochondrial ossification and angiogenesis in mice defficient in membrane-type matrix metalloproteinase Proc Natl Acad Sci USA 2000 97 4052 57